The two companies have announced that they have entered into an exclusive collaboration to develop the OnDosis’ technology for prescription medicines in all pain related indications.
The agreement also entails an option for Grünenthal to an exclusive worldwide license to the technology in these indications.
First partnering deal
The agreement is the first partnering deal for life science startup OnDosis on their technology. While this agreement covers the indication area pain; other focus areas of OnDosis, like ADHD and immunosuppression, remain available for further cooperation with third parties, states the company.
“We are thrilled to enter our first partnering agreement with the leading pain company Grünenthal to further explore how our technology can generate added value for pain patients. This agreement is obviously an import milestone and a clear evidence of the interest in our technology,” says Martin Olovsson, CEO of OnDosis.
As part of the agreed terms, OnDosis will receive a technology access fee in addition to later development and regulatory milestone payments, as well as sales related royalties. Financial terms of the agreement were not disclosed.